arrow_back Trending Legislation
Share share

Stem Cell and Cord Blood Programs Reauthorized and Funded Through 2031

This act extends funding and operations for programs supporting stem cell transplants and cord blood banks. This means individuals needing these therapies will continue to have access, and research and development in this field will proceed, potentially improving the quality of life for many patients.
Key points
The C.W. Bill Young Cell Transplantation Program will receive an additional $33,009,000 annually for fiscal years 2027-2031.
The national cord blood inventory, crucial for patients seeking donors, has been extended until 2031.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Print number: HR 5160
Sponsor: Rep. Smith, Christopher H. [R-NJ-4]
Process start date: 2025-09-04
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Stem Cell and Cord Blood Programs Reauthorized and Funded Through 2031

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 5160.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-09-04.

What are the main provisions?

Key points include:

  • The C.W. Bill Young Cell Transplantation Program will receive an additional $33,009,000 annually for fiscal years 2027-2031.
  • The national cord blood inventory, crucial for patients seeking donors, has been extended until 2031.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Smith, Christopher H. [R-NJ-4].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

Analysis and Potential Impact of HR 5160

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health